RONY CARLOS PRETI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- Short-term effects of intravitreal bevacizumab in contrast sensitivity of patients with diabetic macular edema and optimizing glycemic control(2019) MOTTA, Augusto A. L.; BONANOMI, Maria Teresa B. C.; FERRAZ, Daniel A.; PRETI, Rony C.; SOPHIE, Raafay; ABALEM, Maria F.; QUEIROZ, Marcia S.; PIMENTEL, Sergio L. G.; TAKAHASHI, Walter Y.; DAMICO, Francisco M.Aims: To analyze contrast sensitivity of intravitreal bevacizumab injections with optimizing glycemic control versus optimizing glycemic control (in combination with sham injections) in eyes with Diabetic Macular Edema (DME). Design: Prospective, interventional, masked, randomized controlled trial. Methods: Forty-one eyes of 34 patients with type 2 diabetes mellitus and DME with glycated hemoglobin (HbA1c) < 11% received either intravitreal bevacizumab injection (Group 1) or sham injection (Group 2) at 0 and 6 weeks along with optimizing glycemic control. Mean change in best-corrected visual acuity (BCVA), contrast sensitivity (CS), optical coherence tomography (OCT)-measured by central macular thickness (CMT) were compared and correlated at baseline, 2, 6 and 12 weeks. Results: The study showed a mean CS improved in group 1 from 1.14 +/- 0.36 logCS to 1.32 +/- 0.24 logCS and also in group 2 from 1.11 +/- 0.29 logCS to 1.18 +/- 0.29 logCS at 12 weeks (P = 0.12). CS and CMT promptly decreased in group 1 compared to group 2 at 2 weeks (Delta CS = 0.15 +/- 0.25 vs. 0.03 +/- 0.15 logCS; P = 0.04; Delta CMT = 116 +/- 115 vs. 17 +/- 71 mu m; P = 0.01). There was a mean reduction of approximately 0.5% in HbA1c levels in both groups at 12 weeks (P = 0.002). Conclusion: The use of bevacizumab in combination with optimizing glycemic control results in earlier improvement of contrast sensitivity in type 2 diabetes patients with DME. However, the optimizing glycemic control itself has shown also to be effective at 12 weeks.
- The effect of laser pan-retinal photocoagulation with or without intravitreal bevacizumab injections on the OCT-measured macular choroidal thickness of eyes with proliferative diabetic retinopathy(2017) PRETI, Rony C.; MUTTI, Anibal; FERRAZ, Daniel A.; ZACHARIAS, Leandro C.; NAKASHIMA, Yoshitaka; TAKAHASHI, Walter Y.; MONTEIRO, Mario L. R.OBJECTIVES: To investigate the effect of laser pan-retinal photocoagulation with or without intravitreal bevacizumab injections on macular choroidal thickness parameters in eyes with high-risk proliferative diabetic retinopathy. METHODS: High-risk proliferative diabetic retinopathy patients undergoing laser treatment were prospectively enrolled in this study. One eye was randomly selected for laser treatment combined with bevacizumab injections, study group, whereas the corresponding eye was subjected to laser treatment alone, control group. Spectral-domain optical coherence tomography with enhanced depth imaging was used to measure the macular choroidal thickness prior to and 1 month after treatment. Measurements in both groups were compared. Clinicaltrials. gov: NCT01389505. RESULTS: Nineteen patients (38 eyes) with a mean +/- standard deviation age of 53.4 +/- 9.3 years were evaluated, and choroidal thickness measurements for 15 patients were used for comparison. The greatest measurement before treatment was the subfoveal choroidal thickness (341.68 +/- 67.66 mm and 345.79 +/- 83.66 mm for the study and control groups, respectively). No significant difference between groups was found in terms of macular choroidal thickness measurements at baseline or after treatment. However, within-group comparisons revealed a significant increase in choroidal thickness parameters in 10 measurements in the study group and in only 5 temporal measurements in the control group when 1-month follow-up measurements were compared to baseline values. CONCLUSIONS: The macular choroidal thickness does not appear to be significantly influenced by laser treatment alone but increases significantly when associated with bevacizumab injections in patients with proliferative diabetic retinopathy and macular edema. Because bevacizumab injections reduce short-term laser pan-retinal photocoagulation-induced macular edema, our findings suggest that the choroid participates in its pathogenesis.
conferenceObject Intravitreal Ranibizumab Combined with Panretinal Photocoagulation in Patients with Treatment-Naive Proliferative Diabetic Retinopathy(2013) FERRAZ, Daniel; SOPHIE, Raafay; BITTENCOURT, Millena; PRETI, Rony; VAZQUEZ, Lisa; MOTTA, Augusto; HANOUT, Mostafa; SEPAH, Yasir; Quan Dong Nguyen; TAKAHASHI, Walterarticle 39 Citação(ões) na Scopus A RANDOMIZED CONTROLLED TRIAL OF PANRETINAL PHOTOCOAGULATION WITH AND WITHOUT INTRAVITREAL RANIBIZUMAB IN TREATMENT-NAIVE EYES WITH NON-HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY(2015) FERRAZ, Daniel A.; VASQUEZ, Lisa M.; PRETI, Rony C.; MOTTA, Augusto; SOPHIE, Raafay; BITTENCOURT, Millena G.; SEPAH, Yasir J.; MONTEIRO, Mario L. R.; Quan Dong Nguyen; TAKAHASHI, Walter YukihikoPurpose: To compare the efficacy of panretinal photocoagulation (PRP) and intravitreal ranibizumab injection with PRP alone in patients with treatment-naive bilateral non-high-risk proliferative diabetic retinopathy. Methods: Sixty eyes of 30 patients were randomized either to the study group (SG) receiving PRP plus 2 ranibizumab injections or to the control group (CG) receiving PRP alone. Mean change in best-corrected visual acuity and in optical coherence tomography were compared at baseline and 1, 3, and 6 months. Results: Best-corrected visual acuity was significantly better at 6 months in the SG; however, there was decrease in best-corrected visual acuity in the CG. Central macula thickness decreased significantly at 6 months in SG when compared with baseline (-47.6 mm, P < 0.001) and did not reveal significant difference in the CG. In eyes with diabetic macular edema, best-corrected visual acuity increased by 3.6 letters (P = 0.06) in the SG and decreased by 4.4 letters in the CG (P = 0.003). Central macula thickness decreased by 69.3 mm (P = 0.001) in the SG and decreased by 45.5 mm (P = 0.11) in the CG. Conclusion: Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non-high-risk proliferative diabetic retinopathy and diabetic macular edema.- Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics(2013) FERRAZ, Daniel Araujo; MORITA, Celso; PRETI, Rony Carlos; NASCIMENTO, Vinicius Paganini; MAIA JUNIOR, Otacilio Oliveira; BARROS, Andre Carvalho de; TAKAHASHI, Beatriz Sayuri; TAKAHASHI, Walter YukihikoPurpose: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) or triamcinolone (IVT) on the rate of early postvitrectomy hemorrhage in proliferative diabetic retinopathy (PDR). Methods: Eligible eyes were assigned randomly to 1 of 3 groups: the IVB group received 1.25 mg bevacizumab, the IVT group received 4,0mg triamcinolone and the control group underwent a sham procedure. The primary outcome measure was the incidence of early postvitrectomy hemorrhage. Secondary outcome measures included changes in visual acuity (BCVA) and adverse events. Results: Twenty and seven eyes, 9 in each group were randomized. The incidence of vitreous hemorrhage was lower in the IVB group (p=0.18). Postoperative vitreous hemorrhage at 1 month also was less in the IVB group compared with the control group (p >= 0.05). The rate of bleeding immediately after surgery was higher in IVT group with 4 (44.4%) cases. The overall mean visual acuity was 1.72 +/- 0.37 logMAR preoperatively and 1.32 +/- 0.73 logMAR in 6 months after surgery. Accessing visual acuity by group evidenced that the IVB group had initial mean logMAR VA of 1.87 and 1.57 logMAR VA at the six months (p = 0.84). In IVT group, initial mean VA was 1.75 logMAR and 0.96 logMAR VA at six months (p <= 0.001). And in control group, the initial mean VA was 1.85 logMAR and 1.57 logMAR VA at six months (p= 0.34). Conclusion: Intravitreal injection of bevacizumab 1 week before vitrectomy seems to reduce the incidence of early postvitrectomy hemorrhage in diabetic patients. There was a better visual acuity outcome in the triamcinolone group.
conferenceObject EVALUATION OF CHOROIDAL THICKNESS IN HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION ASSOCIATED OR NOT WITH INTRAVITREAL BEVACIZUMAB INJECTIONS: A 3 MONTHS, RANDOMIZED, CONTROLLED AND MASKED CLINICAL TRIAL(2013) PRETI, Rony; MUTTI, Anibal; VAZQUEZ, Lisa; FERRAZ, Daniel; ZACHARIAS, Leandro; CARRA, Mario; PELAYES, David; MONTEIRO, Mario; TAKAHASHI, WalterconferenceObject Contrast sensitivity evaluation in high-risk treatment-naive proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal Ranibizumab.(2014) FERRAZ, Daniel Araujo; VASQUEZ, Lisa; MOTTA, Augusto; PRETI, Rony C.; SOPHIE, Raafay; BITTENCOURT, Millena Gomes; MONTEIRO, Mario L. R.; TAKAHASHI, Walter Y.conferenceObject Short-Term Effects of Intravitreal Bevacizumab in Contrast Sensitivity of Patients with Diabetic Macular Edema and Optimizing Glycemic Control(2018) MOTTA, Augusto; BONANOMI, Maria Teresa B. C.; FERRAZ, Daniel Araujo; PRETI, Rony Carlos; SOPHIE, Raafay; MEDINA, Flavio Mac Cord; ABALEM, Maria Fernanda; QUEIROZ, Marcia; PIMENTEL, Sergio Luis G.; TAKAHASHI, Walter Yukihiko; DAMICO, Francisco Max- Idiopathic polypoidal choroidal vasculopathy masquerading as choroidal tumors: one year follow-up of a peripheral lesion(2015) PRETI, Rony Carlos; MONTEIRO, Mario Luiz Ribeiro; MORITA, Celso; HELAL JUNIOR, John; ZACHARIAS, Leandro Cabral; FERRAZ, Daniel Araujo; PELAYES, David E.; TAKAHASHI, Walter YukihikoThis case report describes peripheral idiopathic polypoidal choroidal vasculopathy (IPCV) with a collection of small aneurysmal dilations that masqueraded as choroidal tumors in an elderly patient. A 68-year-old African American woman was referred to us with a suspected diagnosis of asymptomatic vascular choroidal tumor and choroidal capillary hemangioma, affecting the temporal peripheral fundus. Upon examination, optical coherence tomography (OCT) revealed two large hemorrhagic pigment epithelium detachments (PED), and indocyanine green angiography (ICG) confirmed the diagnosis of IPCV. One year later, there was reduction in the hemorrhagic pigment epithelium detachments and the lesion took on a different appearance, resembling a choroidal osteoma. No treatment was necessary despite the presence of multiple polyps. IPCV is a rare condition that can resemble other choroidal diseases depending on the stage of presentation. OCT is the best tool to determine the characteristics of the lesions, and indocyanine green angiography should be used to confirm the diagnosis. Not all cases require treatment.